Cancer is a disease that results from abnormal cell growth. There are different types of cancer depending on the part they occur in and at present, this is one of the largest diseases resulting in deaths of both adults and children. Cancer immunology is the study of the immune system to understand the development of cancer. Oncolytic virology is the use of the oncolytic virus to infect and subsequently kill cancer cells. The cancer immunology and oncolytic virology market uses both these procedures to effectively treat the disease.
The rising cases of cancer in both adults and children have forced medical practitioners to look at more effective treatment processes. This is one reason why the global cancer immunology and oncolytic virology market is set for growth in the future. The availability of better research centers around the world has also created more interest in this field. Both these technologies are considered exciting and very effective and hence healthcare institutions are allocating budgets to work on these areas.
The global cancer immunology and oncolytic virology technologies market is a comprehensive study of how the market has been in the past, how it is projected to be at present and how it is projected to grow in the future. The global, regional and individual company level analysis is done by the report and factors like growth rate, CAGR and the revenue generated by this market at different levels are investigated. This report takes date from years 2015 and 2016 and projects it up to the year 2021.
The different segments that this report deals with are synthetic interleukins, colony-stimulating factors, therapeutic monoclonal antibodies and, interferons. This report gives a special focus to checkpoint inhibitors in the therapeutic monoclonal antibodies category. There are two broad treatment options for cancer and this report talks in detail about both early-stage and late-stage oncolytic viruses. The potential for growth of both these types of cancer immunology and oncolytic virology techniques and the revenue each type will create for the market are analyzed. It provides detailed epidemiological information about the techniques and treatment plans also.
The geographical changes that affect the cancer immunology and oncolytic virology market are investigated in detail by the report. Areas like North America, Europe, Asia-Pacific and the rest of the world are considered for analysis. The report mentions in detail the individual market share each of these regions will hold and their potential for revenue generation. The export and import of devices needed for these processes are talked about too. The study also identifies submarkets that will be generated by this industry. The scope for growth of these submarkets is explained too.
A latest study published in the Clinical Cancer Research journal talks about how the common cold virus can be used to treat bladder cancer. The researchers used a common strain of this virus and used it as an oncolytic agent to understand its effects on non muscle-invasive cancer of the bladder.
Profiles of leading companies in the industry:
Daiichi Sankyo Co.
F Hoffmann La Roche Ag
Gilead Sciences Inc.
Immunocellular Therapeutics Ltd.
Inovio Pharmaceuticals Inc.
Kadmon Pharmaceuticals Corp.
Kite Pharmaceuticals Inc.
Kyowa Hakko Kirin Co. Ltd.
Ligand Pharmaceuticals Inc.
Lokon Pharmaceuticals Ab
Merck & Co.
Novartis Pharma Services Ag
Oncolys Biopharma Inc.
Oncolytics Biotech Inc.
Oncomed Pharmaceuticals Inc.
Oncos Therapeutics Ltd.
Ono Pharmaceutical Co.
Otsuka Pharmaceutical Co., Ltd.
Portola Pharmaceuticals Inc.
Provectus Biopharmacueticals Inc.
Psioxus Therapeutics Ltd.
Shanghai Sunway Biotech Co. Ltd.
Shenzhen Sibiono Gentech
Sillajen Biotherapeutics Inc.
Takara Bio Inc.
Takeda Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Tg Therapeutics Inc.
Tracon Pharmaceuticals Inc.
Virttu Biologics Ltd
Western Oncolytics Ltd.
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)